Vertex Pharma (VRTX) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY26 Revenue Guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $525.39 -0.8%
Financial Fact:
Total costs and expenses: 432.51M
Today's EPS Names:
FWDI, GO, BATL, More
Financial Fact:
Total costs and expenses: 432.51M
Today's EPS Names:
FWDI, GO, BATL, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $4.73, $0.01 better than the analyst estimate of $4.72. Revenue for the quarter came in at $3.33 billion versus the consensus estimate of $3.22 billion.
GUIDANCE:
Vertex Pharma sees FY2026 revenue of $13.1-13.2 billion, versus the consensus of $13.05 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cencora says Walgreens volumes shift, reaffirms guidance, shares sink
- Valens Semiconductor (VLN) Reports In-Line Q2 EPS, Misses on Revenue; Offers FY26 Revenue Guidance
- Okta upgraded as AI security opportunity boosts outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
